<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607176</url>
  </required_header>
  <id_info>
    <org_study_id>ZY3-CCCX-3-1001</org_study_id>
    <nct_id>NCT02607176</nct_id>
  </id_info>
  <brief_title>Heweizhixie capsuleTherapy on Patients With Diarrhea</brief_title>
  <official_title>A Post -Marketing Drug Evaluation(Phase IV Clinical Trial) to Study the Safety and Efficacy of Heweizhixie Capsule in Patients With Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate safety and efficacy of Heweizhixie Capsule in
      patients with diarrhea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate safety and efficacy of Heweizhixie Capsule in
      patients with diarrhea.This is a Phase 4 Open Label trial, enroll 2400 patients with diarrhea
      Primary Outcome Measure:Percent of subjects with treatment Success

      Secondary Outcome Measures:

      Number of unformed stools passed per 24 h period Time (hours) from first intake to the last
      unformed stools Change from baseline of Leeds dyspepsia questionnaire score Percent of
      subjects with AE.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects with treatment Success</measure>
    <time_frame>3 days</time_frame>
    <description>Percent of subjects with treatment Success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of unformed stools passed per 24 h period</measure>
    <time_frame>per 24 h period</time_frame>
    <description>Number of unformed stools passed per 24 h period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (hours) from first intake to the last unformed stools</measure>
    <time_frame>3 days</time_frame>
    <description>Time (hours) from first intake to the last unformed stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of leeds dyspepsia questionnaire score</measure>
    <time_frame>3 days</time_frame>
    <description>Change from baseline of leeds dyspepsia questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with AE</measure>
    <time_frame>3 days</time_frame>
    <description>Percent of subjects with AE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Heweizhixie capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heweizhixie capsule</intervention_name>
    <description>3 #, Tid, Oral for 3 days</description>
    <arm_group_label>Heweizhixie capsule</arm_group_label>
    <other_name>Changdaoqing capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        3 or more unformed stools in 24 hours Male and female subjects between 18 and 80 years old
        Signed informed consent

        Exclusion Criteria:

        Subjects with serum ALT more than 5ULN or serum Cr more than 442umol/L Subjects are
        pregnant now, likely to become pregnant Subjects, who in the opinion of the Investigator,
        are not suitable candidates for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QingShan Zheng, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingchun He, MD</last_name>
    <phone>+862151322420</phone>
    <phone_ext>+862151322750</phone_ext>
    <email>yingchun.he@drugchina.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongxia Liu, Dr</last_name>
    <phone>+862151323006</phone>
    <phone_ext>+862151322750</phone_ext>
    <email>hongxia.liu@drugchna.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Long hua hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaoyan fei, Dr</last_name>
      <phone>13671578820</phone>
      <phone_ext>64385700</phone_ext>
      <email>23386348@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2015</study_first_submitted>
  <study_first_submitted_qc>November 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>May 20, 2017</last_update_submitted>
  <last_update_submitted_qc>May 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

